<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21709297</article-id><article-id pub-id-type="pmc">3120204</article-id><article-id pub-id-type="publisher-id">0091</article-id><article-id pub-id-type="doi">10.2337/dc11-0091</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group><subject>Pathophysiology/Complications</subject></subj-group></subj-group></article-categories><title-group><article-title>Restriction of Advanced Glycation End Products Improves Insulin Resistance in Human Type 2 Diabetes</article-title><subtitle>Potential role of AGER1 and SIRT1</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>Uribarri</surname><given-names>Jaime</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Weijing</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ramdas</surname><given-names>Maya</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Goodman</surname><given-names>Susan</given-names></name><degrees>RD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pyzik</surname><given-names>Renata</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xue</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Li</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Striker</surname><given-names>Gary E.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vlassara</surname><given-names>Helen</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"/></contrib><aff id="aff1"><sup>1</sup>Department of Medicine, The Mount Sinai School of Medicine, New York, New York</aff><aff id="aff2"><sup>2</sup>Department of Geriatrics, The Mount Sinai School of Medicine, New York, New York</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Helen Vlassara, <email>helen.vlassara@mssm.edu</email>.</corresp><fn><p>J.U. and W.C. share first authorship of this work.</p></fn></author-notes><pub-date pub-type="ppub"><month>7</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>17</day><month>6</month><year>2011</year></pub-date><volume>34</volume><issue>7</issue><fpage>1610</fpage><lpage>1616</lpage><history><date date-type="received"><day>14</day><month>1</month><year>2011</year></date><date date-type="accepted"><day>12</day><month>4</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; 2011 by the American Diabetes Association.</copyright-statement><copyright-year>2011</copyright-year><license license-type="creative-commons"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="1610.pdf"/><abstract><sec id="s1"><title>OBJECTIVE</title><p>Increased oxidative stress (OS) and impaired anti-OS defenses are important in the development and persistence of insulin resistance (IR). Several anti-inflammatory and cell-protective mechanisms, including advanced glycation end product (AGE) receptor-1 (AGER1) and sirtuin (silent mating-type information regulation 2 homolog) 1 (SIRT1) are suppressed in diabetes. Because basal OS in type 2 diabetic patients is influenced by the consumption of AGEs, we examined whether AGE consumption also affects IR and whether AGER1 and SIRT1 are involved.</p></sec><sec id="s2"><title>RESEARCH DESIGN AND METHODS</title><p>The study randomly assigned 36 subjects, 18 type 2 diabetic patients (age 61 &#x000b1; 4 years) and 18 healthy subjects (age 67 &#x000b1; 1.4 years), to a standard diet (&#x0003e;20 AGE equivalents [Eq]/day) or an isocaloric AGE-restricted diet (&#x0003c;10 AGE Eq/day) for 4 months. Circulating metabolic and inflammatory markers were assessed. Expression and activities of AGER1 and SIRT1 were examined in patients&#x02019; peripheral blood mononuclear cells (PMNC) and in AGE-stimulated, AGER1-transduced (AGER1<sup>+</sup>), or AGER1-silenced human monocyte-like THP-1 cells.</p></sec><sec id="s3"><title>RESULTS</title><p>Insulin and homeostasis model assessment, leptin, tumor necrosis factor-&#x003b1; and nuclear factor-&#x003ba;B p65 acetylation, serum AGEs, and 8-isoprostanes decreased in AGE-restricted type 2 diabetic patients, whereas PMNC AGER1 and SIRT1 mRNA, and protein levels normalized and adiponectin markedly increased. AGEs suppressed AGER1, SIRT-1, and NAD<sup>+</sup> levels in THP-1 cells. These effects were inhibited in AGER1<sup>+</sup> but were enhanced in AGER1-silenced cells.</p></sec><sec id="s4"><title>CONCLUSIONS</title><p>Food-derived pro-oxidant AGEs may contribute to IR in clinical type 2 diabetes and suppress protective mechanisms, AGER1 and SIRT1. AGE restriction may preserve native defenses and insulin sensitivity by maintaining lower basal OS.</p></sec></abstract></article-meta></front><body><p>Insulin action is regulated by multiple factors, including SIRT1, a member of the sirtuin (silent mating type information regulation 2 homolog) 1 family of NAD<sup>+</sup> deacetylases, which acts via signaling mediators and transcription factors, including nuclear factor-&#x003ba;B (NF-&#x003ba;B), forkhead box class O, peroxisome proliferator&#x02013;activated receptor-&#x003b3;, and adiponectin (<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B3">3</xref>). Because SIRT1 activity also modulates the functions of monocytes and macrophages, native defenses may play a key role in insulin resistance (IR), and type 2 diabetes (<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>). SIRT1 activity is decreased in diabetes (<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>), as is advanced glycation end product (AGE) receptor-1 (AGER1) (<xref ref-type="bibr" rid="B6">6</xref>). Because AGEs are oxidants that are normally controlled by AGER1 (<xref ref-type="bibr" rid="B7">7</xref>&#x02013;<xref ref-type="bibr" rid="B9">9</xref>), decreased AGER1 may result in increased oxidative stress (OS) and inflammation (<xref ref-type="bibr" rid="B6">6</xref>). In addition, exposure to glycoxidants when AGER1 levels are reduced may have a negative effect on SIRT1, which could contribute to IR.</p><p>The increasing prevalence of IR and type 2 diabetes is directly related to the Western lifestyle and diet (<xref ref-type="bibr" rid="B10">10</xref>). Excessive intake of fats or carbohydrates is thought to play a major role in the development of IR (<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>), although a direct link has not been established. A clear relationship has been found between inflammation, OS, and IR (<xref ref-type="bibr" rid="B13">13</xref>). Therefore, because AGEs increase inflammation and OS in normal subjects, as well as in diabetic patients, they may also play a role in IR.</p><p>Glycoxidants are partially absorbed as food-derived AGE peptides and AGE lipids by mechanisms not fully elucidated (<xref ref-type="bibr" rid="B14">14</xref>). Experiments in animals have shown a strong link between high oral glycoxidant intake, IR, type 2 diabetes, and diabetes complications (<xref ref-type="bibr" rid="B15">15</xref>&#x02013;<xref ref-type="bibr" rid="B18">18</xref>). Direct evidence that oral AGEs promote OS and cause metabolic changes was provided by studies of mice that were pair fed a low-AGE diet or the same diet supplemented with a well defined AGE (methylglyoxal [MG]-BSA) (<xref ref-type="bibr" rid="B16">16</xref>). An excess of AGEs led to OS, IR, and renal/vascular disease, whereas restriction of AGEs, without altering caloric or nutrient intake, reduced OS and inflammation, ameliorated IR, and extended the life span in mice (<xref ref-type="bibr" rid="B16">16</xref>). Clinical studies in healthy subjects, diabetic patients, and individuals with chronic kidney disease showed that AGE restriction substantially reduced OS and inflammation and improved native defenses, including AGER1 (<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B19">19</xref>).</p><p>In the current study, we investigated the relationship between IR and dietary AGEs in type 2 diabetic patients. We report that AGE restriction lowers insulin levels, markers of IR, and inflammation. In addition, the suppressed expression and function of AGER1 and SIRT1 in diabetic peripheral blood mononuclear cells (PMNCs) are nearly normalized by AGE restriction, consistent with restoration of host defenses.</p><sec id="s5"><title>RESEARCH DESIGN AND METHODS</title><sec id="s6"><title>Study design</title><p>The study enrolled 18 type 2 diabetic patients (14 women, 4 men; average age, 61 &#x000b1; 4 years), without renal disease or overt cardiovascular disease, and a usual diet rich in AGE (dietary AGE intake &#x0223c;&#x0003e;20 AGE equivalents [Eq]/day; <xref ref-type="table" rid="T1">Table 1</xref>). All study subjects continued to receive standard medical care: 20% were treated only with diet, and 80% received oral antidiabetic medications, including 15 with metformin and 1 each with pioglitazone, glipizide, and glimepiride; 60% were receiving statins and ACE inhibitors or angiotensin-receptor blockers, and 40% were taking aspirin (81 mg daily).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline clinical characteristics and other parameters in the study population</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="2" align="left" scope="col" colspan="1">Variables</th><th align="center" scope="col" rowspan="1" colspan="1">Diabetes<hr/></th><th align="center" scope="col" rowspan="1" colspan="1">Healthy<hr/></th><th align="center" scope="col" rowspan="1" colspan="1"/></tr><tr><th colspan="1" align="center" scope="colgroup" rowspan="1"><italic>n</italic> = 18</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>n</italic> = 18</th><th align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">61 &#x000b1; 4</td><td align="center" rowspan="1" colspan="1">67 &#x000b1; 1</td><td align="left" rowspan="1" colspan="1">0.165</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">NS</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">32.3 &#x000b1; 1.6</td><td align="center" rowspan="1" colspan="1">27.3 &#x000b1; 1.4</td><td align="left" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Waist circumference (cm)</td><td align="center" rowspan="1" colspan="1">108 &#x000b1; 4</td><td align="center" rowspan="1" colspan="1">93 &#x000b1; 4</td><td align="left" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Fasting blood glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">120 &#x000b1; 14</td><td align="center" rowspan="1" colspan="1">84 &#x000b1; 3</td><td align="left" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Insulin (&#x003bc;U/mL)</td><td align="center" rowspan="1" colspan="1">17 &#x000b1; 1</td><td align="center" rowspan="1" colspan="1">8 &#x000b1; 1</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">HOMA-IR</td><td align="center" rowspan="1" colspan="1">5.00 &#x000b1; 0.51</td><td align="center" rowspan="1" colspan="1">1.66 &#x000b1; 0.24</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Triglycerides (mg/dL)</td><td align="center" rowspan="1" colspan="1">100 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">80 &#x000b1; 9</td><td align="left" rowspan="1" colspan="1">0.157</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">HDL cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">51 &#x000b1; 3</td><td align="center" rowspan="1" colspan="1">72 &#x000b1; 4</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Serum CML (units/mL)</td><td align="center" rowspan="1" colspan="1">17.4 &#x000b1; 1.1</td><td align="center" rowspan="1" colspan="1">12 &#x000b1; 0.5</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Serum MG (nmol/mL)</td><td align="center" rowspan="1" colspan="1">2.6 &#x000b1; 0.10</td><td align="center" rowspan="1" colspan="1">1.1 &#x000b1; 0.06</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Intracellular CML (units/mg)</td><td align="center" rowspan="1" colspan="1">7.9 &#x000b1; 1.8</td><td align="center" rowspan="1" colspan="1">5.7 &#x000b1; 2.3</td><td align="left" rowspan="1" colspan="1">0.005</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Intracellular MG (nmol/mg)</td><td align="center" rowspan="1" colspan="1">0.87 &#x000b1; 0.28</td><td align="center" rowspan="1" colspan="1">0.70 &#x000b1; 0.38</td><td align="left" rowspan="1" colspan="1">0.148</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">8-Isoprostane (pg/mL)</td><td align="center" rowspan="1" colspan="1">234 &#x000b1; 14</td><td align="center" rowspan="1" colspan="1">130 &#x000b1; 11</td><td align="left" rowspan="1" colspan="1">0.033</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Plasma leptin (ng/mL)</td><td align="center" rowspan="1" colspan="1">36 &#x000b1; 3.6</td><td align="center" rowspan="1" colspan="1">15 &#x000b1; 2.7</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Plasma adiponectin (&#x000b5;g/mL)</td><td align="center" rowspan="1" colspan="1">7 &#x000b1; 0.5</td><td align="center" rowspan="1" colspan="1">16 &#x000b1; 2.6</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">AGER1 (mRNA)</td><td align="center" rowspan="1" colspan="1">133 &#x000b1; 11</td><td align="center" rowspan="1" colspan="1">225 &#x000b1; 28</td><td align="left" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">RAGE (mRNA)</td><td align="center" rowspan="1" colspan="1">532 &#x000b1; 77</td><td align="center" rowspan="1" colspan="1">464 &#x000b1; 67</td><td align="left" rowspan="1" colspan="1">0.511</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">SIRT1 (mRNA)</td><td align="center" rowspan="1" colspan="1">282 &#x000b1; 27</td><td align="center" rowspan="1" colspan="1">378 &#x000b1; 27</td><td align="left" rowspan="1" colspan="1">0.029</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">p66<sup>shc</sup> (mRNA)</td><td align="center" rowspan="1" colspan="1">113 &#x000b1; 20</td><td align="center" rowspan="1" colspan="1">66 &#x000b1; 6</td><td align="left" rowspan="1" colspan="1">0.047</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">NOX p47<sup>phox</sup> (mRNA)</td><td align="center" rowspan="1" colspan="1">220 &#x000b1; 24</td><td align="center" rowspan="1" colspan="1">125 &#x000b1; 19</td><td align="left" rowspan="1" colspan="1">0.026</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">TNF-&#x003b1; (ng/mg protein in PMNCs)</td><td align="center" rowspan="1" colspan="1">18.5 &#x000b1; 0.8</td><td align="center" rowspan="1" colspan="1">10 &#x000b1; 0.5</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Caloric intake (kcal/day)</td><td align="center" rowspan="1" colspan="1">2,329 &#x000b1; 248</td><td align="center" rowspan="1" colspan="1">2,120 &#x000b1; 215</td><td align="left" rowspan="1" colspan="1">0.934</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">AGE intake (AGE Eq/day)</td><td align="center" rowspan="1" colspan="1">23 &#x000b1; 3</td><td align="center" rowspan="1" colspan="1">18 &#x000b1; 1.3</td><td align="left" rowspan="1" colspan="1">0.135</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Creatinine clearance<xref ref-type="table-fn" rid="t1n1">*</xref></td><td align="center" rowspan="1" colspan="1">92 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">98 &#x000b1; 4</td><td align="left" rowspan="1" colspan="1">0.431</td></tr></tbody></table><table-wrap-foot><fn><p>Continuous data are expressed as mean &#x000b1; SEM and categoric data as <italic>n</italic>. <italic>P</italic> values reflect differences between means of diabetic and healthy subjects at baseline. NS, not significant.</p></fn><fn id="t1n1"><p>*Calculated as mL/min/1.73 m<sup>2</sup>.</p></fn></table-wrap-foot></table-wrap><p>They were randomly assigned to an AGE-restricted diet (<italic>n</italic> = 12) or their usual diet (<italic>n</italic> = 6) for 4 months. The AGE-restricted group received instructions on how to modify cooking time and temperature but not the quantity or nutrient composition of food. They were advised to boil, poach, stew, or steam food and to avoid frying, baking, or grilling, methods, which limit dietary AGE intake by &#x0223c;40&#x02013;50% (<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>). The control group comprised 18 age-matched (age 67 &#x000b1; 1.4 years), healthy volunteers selected from a larger well characterized cohort that was randomized to the same AGE-restricted diet for 4 months (<xref ref-type="bibr" rid="B9">9</xref>).</p><p>A dietitian monitored participants by telephone 1&#x02013;2 times per week and at monthly clinic visits. The study diets were designed to maintain daily requirements of calories and nutrients in both arms but to restrict AGE intake only on the AGE-restricted arm. Nutritional intake was closely monitored in both groups.</p><p>The study and consent forms were approved by the Mount Sinai School of Medicine Institutional Review Board. All participants provided informed consent.</p></sec><sec id="s7"><title>Human subjects</title><p>Participants received a physical examination and provided a fasting blood sample and a 24-h urine collection at baseline and at 4 months. Routine blood and urine tests were performed by the hospital clinical laboratory.</p></sec><sec id="s8"><title>Dietary intake</title><p>Daily dietary AGE content, from 3-day food records that emphasized cooking methods, was estimated from a database that listed AGE values of &#x0223c;560 foods and was expressed as AGE equivalents/day (AGE Eq = 1,000 kilounits) (<xref ref-type="bibr" rid="B20">20</xref>). The 3-day food record is based on established guidelines developed to allow estimation of food and beverage consumption at home and away from home. The dietitian reviewed the record with the subject, probing for details on portion sizes and preparation methods, to ensure accuracy and compliance. Nutrient calculations were estimated by using the Food Processor 10.1 nutrient software program (ESHA Research, Salem, OR).</p></sec><sec id="s9"><title>Assessment of AGEs, insulin, and inflammation</title><p>Derivatives of <italic>N</italic><sup>&#x003b5;</sup>-carboxymethyl-lysine (CML) and methylglyoxal (MG) in serum were quantified by established enzyme-linked immunosorbent assays (ELISAs) using monoclonal antibodies (4G9 and MG3D11) (<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B21">21</xref>), validated against synthetic standards, CML-BSA (23 modified lysines/mol) and MG-BSA (20 MG-modified arginines/mol), based on high-performance liquid chromatography and gas chromatography-mass spectroscopy (<xref ref-type="bibr" rid="B21">21</xref>). Insulin was measured by an ELISA kit (ALPCO Diagnostics, Salem, NH). IR was estimated by the homeostasis model assessment (HOMA) index as [FI &#x000d7; (fasting glucose/22.5)], where FI is insulin in microunits per milliliterand fasting glucose is in millimoles per liter(<xref ref-type="bibr" rid="B9">9</xref>). ELISA kits were used for measuring plasma leptin, adiponectin (Millipore, Billerica, MA), and PMNC tumor necrosis factor (TNF)-&#x003b1; (Biosource International, Camarillo, CA).</p></sec><sec id="s10"><title>PMNCs</title><p>PMNCs were separated from fasting, EDTA-anticoagulated blood by Ficoll-Hypaque Plus gradient (American Biosciences, Uppsala, Sweden) and used to isolate mRNA and protein (<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B19">19</xref>). Total RNA was extracted by TRIzol (Invitrogen-Molecular Probes, Inc., Eugene, OR). The extracted RNA had an optical density of 280/260 ratio of between 1.8 and 2.0. Total RNA was reverse-transcribed using Superscript III RT (Invitrogen, Carlsbad, CA).</p></sec><sec id="s11"><title>Cell culture and transient transfection</title><p>THP-1 human monocytes (1 &#x000d7; 10<sup>6</sup>/mL) (American Type Culture Collection, Manassas, VA) were cultured in RPMI-1640 medium (1% FBS). THP-1 cells were transfected with AGER1, SIRT1 or short-hairpin RNA AGER1 (0.5 &#x000b5;g of DNA) by using the human monocyte cell line nucleofector kit (Amaxa Biosystems, Cologne, Germany). Quiescent cells were exposed to CML-BSA, MG-BSA, or BSA, with or without the following inhibitors: sirtinol (10 &#x000b5;mol/L; Calbiochem, La Jolla, CA); <italic>N</italic>-acetylcysteine ([NAC], 5 mmol/L; Sigma-Aldrich, St. Louis, MO); apocynin (300 &#x000b5;mol/L; Sigma-Aldrich); and Mn superoxide dismutase (1,000 units/mL; Sigma-Aldrich).</p></sec><sec id="s12"><title>AGEs used for in vitro studies</title><p>Synthetic preparations of CML-BSA (23 CML-Lys/mol), MG-BSA (22 MG-Arg/mol) (<xref ref-type="bibr" rid="B21">21</xref>), and BSA (Fraction V; Sigma-Aldrich) were rendered LPS-negative before use by a Detoxigel column (Pierce, Rockford, IL), based on Limulus assay (BioWhittaker, Walkerville, MD).</p></sec><sec id="s13"><title>Quantitative RT-PCR assay</title><p>AGER1, receptor for AGE (RAGE), the 66-kDa protein from the src homology and collagen homology domain (p66<sup>shc</sup>), SIRT1, and NADPH oxidase 1 (NOX) p47<sup>phox</sup> mRNA levels were assessed by quantitative SYBR Green real-time PCR (<xref ref-type="bibr" rid="B9">9</xref>). Primer sequences were as follows:<list list-type="simple"><list-item><p>AGER1, forward primer 5&#x02032;-CTGGGGCTCTTCATCTTCAG-3&#x02032;, reverse primer 5&#x02032;-GTTGCATCTCCCACAGAGGT-3&#x02032;;</p></list-item><list-item><p>RAGE, forward primer 5&#x02032;-AGGAGCGTGCAGAACTGAAT-3&#x02032;, reverse primer 5&#x02032;-TTGGCAAGGTGGGGTTATAC-3&#x02032;;</p></list-item><list-item><p>p66<sup>shc</sup>, forward primer 5&#x02032;-AGGAAGGGCAGCTGATGAT-3&#x02032;, reverse primer 5&#x02032;-GCGTGGGCTTATTGACAAAG-3&#x02032;;</p></list-item><list-item><p>NOXp47<sup>phox</sup>, forward primer 5&#x02032;-ACAGCGTCCGTTTTCTGC-3&#x02032;, reverse primer 5&#x02032;-AGCGGTTCAGGATGAGGTC-3&#x02032;; and</p></list-item><list-item><p>SIRT1, forward primer 5&#x02032;-CGGAAACAATACCTCCACCT-3&#x02032;, reverse primer 5&#x02032;-CACCCCAGCTCCAGTTAGAA-3&#x02032;.</p></list-item></list>Emission from each sample was recorded during thermal cycling, and the raw fluorescence data were processed using Sequence Detection System software (Applied Biosystems, Carlsbad, CA) to produce threshold cycle (Ct) values for each sample. &#x003b2;-Actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) housekeeping genes were used for internal normalization. The transcript copy number of target genes was determined based on their Ct values (<xref ref-type="bibr" rid="B9">9</xref>).</p></sec><sec id="s14"><title>Western analysis and immunoprecipitation</title><p>Cell proteins were separated on 8% SDS-PAGE gels, transferred onto nitrocellulose (NT) membranes for probing with primary and secondary antibodies, and visualized by an enhanced chemiluminescence system (Roche, Mannheim, Germany) (<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B18">18</xref>). For immunoprecipitation, the lysate (300 &#x000b5;g protein) was incubated overnight at 4&#x000b0;C with the appropriate antibody, followed by 60 &#x003bc;L protein A/G plus agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA) for 2 h. Bound immune complexes in radioimmunoprecipitation assay lysis buffer were used for immunoblotting after SDS-PAGE and NT transfer (<xref ref-type="bibr" rid="B9">9</xref>).</p></sec><sec id="s15"><title>NF-&#x003ba;B p65 acetylation</title><p>Cells (PMNCs, THP-1) were disrupted in lysis buffer (Sigma-Aldrich, C2978), and 100 &#x000b5;g protein was immunoprecipitated with anti-NF-&#x003ba;B-p65 (Santa Cruz Biotechnology) at 4&#x000b0;C overnight. A total of 60 &#x000b5;L protein agarose (A/G) beads were added, and immunoprecipitates were immunoblotted for acetyl-lysine residues (<xref ref-type="bibr" rid="B4">4</xref>). For densitometric analysis, acetyl-p65 was normalized for total p65.</p></sec><sec id="s16"><title>NAD/NADH determination</title><p>NAD and NADH were measured using an Amplite Fluorimetric NAD/NADH assay kit (AAT Bioquest, Inc., Sunnyvale, CA). Cells (wild-type or AGER1-transfected) were lysed after stimulation with MG-BSA (60 &#x000b5;g/mL) for 72 h in the presence or absence of antioxidants NAC (5 mmol/L) and apocynin (300 &#x000b5;mol/L).</p></sec><sec id="s17"><title>Statistical analysis</title><p>Data in the tables and figures are presented as means &#x000b1; SEM. The Kolmogorov-Smirnov goodness-of-fit test was used to test for normal distribution. Variables not normally distributed were logarithmically converted for analyses. Differences of means between groups were analyzed by the Student <italic>t</italic> test or ANOVA, followed by the Bonferroni correction for multiple comparisons, depending on the number of groups. Correlation analyses were also examined by the Pearson correlation coefficient.</p><p>Significance of changes during the interventional study was assessed by comparing <italic>1</italic>) change of means between baseline and end of study within each group by paired <italic>t</italic> test, <italic>2</italic>) percentage of change from baseline to the end of the study between the AGE-restricted and the regular AGE diet groups by the Mann-Whitney test, and <italic>3</italic>) differences between the means of both groups at the end of the study by unpaired <italic>t</italic> test. Significant differences were defined as a value of <italic>P</italic> &#x0003c; 0.05 and are based on two-sided tests. Data analysis was performed in consultation with a statistician, using SPSS 17.0 software (SPSS, Chicago, IL).</p></sec></sec><sec sec-type="results" id="s18"><title>RESULTS</title><sec id="s19"><title>Baseline data</title><p>The type 2 diabetic patients, age- and sex-matched with nondiabetic control subjects, had similar levels of creatinine clearance (<xref ref-type="table" rid="T1">Table 1</xref>). Compared with healthy subjects, type 2 diabetic participants had significantly higher fasting blood glucose, plasma insulin, HOMA, BMI, waist circumference, serum CML (sCML), serum MG (sMG), and leptin but lower adiponectin. They also had significantly higher levels of serum AGEs and plasma 8-isoprostanes (<xref ref-type="table" rid="T1">Table 1</xref>).</p><p>AGER1 and SIRT1 mRNA levels in PMNCs from diabetic subjects were significantly lower than in healthy subjects (<xref ref-type="table" rid="T1">Table 1</xref>). Concentrations of pro-OS p66<sup>shc</sup> and NAPDH oxidase p47<sup>phox</sup> mRNA and TNF-&#x003b1; protein, a proinflammatory cytokine, were elevated, as were intracellular AGEs (iCML; <xref ref-type="table" rid="T1">Table 1</xref>). These data were consistent with high baseline OS.</p></sec><sec id="s20"><title>Intervention data</title><sec id="s21"><title>Serum and plasma changes after AGE restriction.</title><p>AGE restriction (by 50%), without altering nutrient intake, led to markedly lower levels of sCML and sMG, as well as 8-isoprostanes in type 2 diabetic subjects (<xref ref-type="table" rid="T2">Table 2</xref>, Fig. 1<italic>A</italic>). Plasma insulin, HOMA, and leptin levels were also decreased by &#x0223c;30% below baseline by AGE restriction (<xref ref-type="table" rid="T2">Table 2</xref>, <xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic></xref>). However, adiponectin levels were doubled after AGE restriction, resulting in a markedly lower leptin/adiponectin ratio (<xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic></xref>, inset).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Intervention: Changes in biochemical, metabolic, and cellular parameters in diabetic patients and in healthy control subjects after AGE restriction</p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="3" align="center" scope="col" colspan="1">Variable</th><th colspan="6" align="center" scope="colgroup" rowspan="1">Diabetic patients<hr/></th><th rowspan="3" align="center" scope="col" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="t2n3">&#x02021;</xref></th><th rowspan="3" align="center" scope="col" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="t2n4">&#x000a7;</xref></th></tr><tr><th colspan="3" align="center" scope="colgroup" rowspan="1">AGE-restricted diet (<italic>n</italic> = 12)<hr/></th><th colspan="3" align="center" scope="colgroup" rowspan="1">Regular AGE diet (<italic>n</italic> = 6)<hr/></th></tr><tr><th colspan="1" align="center" scope="colgroup" rowspan="1">Baseline</th><th align="center" scope="col" rowspan="1" colspan="1">End</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="t2n1">*</xref></th><th align="center" scope="col" rowspan="1" colspan="1">Baseline</th><th align="center" scope="col" rowspan="1" colspan="1">End</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="t2n2">&#x02020;</xref></th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1">sCML (units/mL)</td><td align="center" rowspan="1" colspan="1">17.1 &#x000b1; 1.3</td><td align="center" rowspan="1" colspan="1">11.6 &#x000b1; 1.1</td><td align="char" char="." rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">17.8 &#x000b1; 2</td><td align="center" rowspan="1" colspan="1">24.2 &#x000b1; 4</td><td align="char" char="." rowspan="1" colspan="1">0.199</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="char" char="." rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">sMG (nmol/mL)</td><td align="center" rowspan="1" colspan="1">2.6 &#x000b1; 0.2</td><td align="center" rowspan="1" colspan="1">1.8 &#x000b1; 0.2</td><td align="char" char="." rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">2.6 &#x000b1; 0.2</td><td align="center" rowspan="1" colspan="1">3.5 &#x000b1; 0.3</td><td align="char" char="." rowspan="1" colspan="1">0.039</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="char" char="." rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">iCML (units/mg)</td><td align="center" rowspan="1" colspan="1">8.1 &#x000b1; 0.9</td><td align="center" rowspan="1" colspan="1">6.5 &#x000b1; 0.5</td><td align="char" char="." rowspan="1" colspan="1">0.148</td><td align="center" rowspan="1" colspan="1">7.6 &#x000b1; 0.3</td><td align="center" rowspan="1" colspan="1">10.5 &#x000b1; 0.9</td><td align="char" char="." rowspan="1" colspan="1">0.023</td><td align="char" char="." rowspan="1" colspan="1">0.007</td><td align="char" char="." rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">iMG (nmol/mg)</td><td align="center" rowspan="1" colspan="1">0.97 &#x000b1; 0.10</td><td align="center" rowspan="1" colspan="1">0.52 &#x000b1; 0.05</td><td align="char" char="." rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">0.76 &#x000b1; 0.12</td><td align="center" rowspan="1" colspan="1">1.08 &#x000b1; 0.15</td><td align="char" char="." rowspan="1" colspan="1">0.117</td><td align="char" char="." rowspan="1" colspan="1">0.003</td><td align="char" char="." rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">AGER1 (mRNA)</td><td align="center" rowspan="1" colspan="1">125 &#x000b1; 15</td><td align="center" rowspan="1" colspan="1">193 &#x000b1; 20</td><td align="char" char="." rowspan="1" colspan="1">0.018</td><td align="center" rowspan="1" colspan="1">144 &#x000b1; 16</td><td align="center" rowspan="1" colspan="1">97 &#x000b1; 16</td><td align="char" char="." rowspan="1" colspan="1">0.069</td><td align="char" char="." rowspan="1" colspan="1">0.003</td><td align="char" char="." rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">RAGE (mRNA)</td><td align="center" rowspan="1" colspan="1">530 &#x000b1; 111</td><td align="center" rowspan="1" colspan="1">270 &#x000b1; 70</td><td align="char" char="." rowspan="1" colspan="1">0.064</td><td align="center" rowspan="1" colspan="1">467 &#x000b1; 110</td><td align="center" rowspan="1" colspan="1">690 &#x000b1; 109</td><td align="char" char="." rowspan="1" colspan="1">0.179</td><td align="char" char="." rowspan="1" colspan="1">0.002</td><td align="char" char="." rowspan="1" colspan="1">0.018</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">SIRT-1 (mRNA)</td><td align="center" rowspan="1" colspan="1">268 &#x000b1; 24</td><td align="center" rowspan="1" colspan="1">409 &#x000b1; 53</td><td align="char" char="." rowspan="1" colspan="1">0.040</td><td align="center" rowspan="1" colspan="1">300 &#x000b1; 53</td><td align="center" rowspan="1" colspan="1">205 &#x000b1; 38</td><td align="char" char="." rowspan="1" colspan="1">0.176</td><td align="char" char="." rowspan="1" colspan="1">0.007</td><td align="char" char="." rowspan="1" colspan="1">0.010</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">TNF-&#x003b1; (ng/mg)</td><td align="center" rowspan="1" colspan="1">18 &#x000b1; 1</td><td align="center" rowspan="1" colspan="1">14.4 &#x000b1; 2</td><td align="char" char="." rowspan="1" colspan="1">0.078</td><td align="center" rowspan="1" colspan="1">20 &#x000b1; 2</td><td align="center" rowspan="1" colspan="1">26 &#x000b1; 2</td><td align="char" char="." rowspan="1" colspan="1">0.030</td><td align="char" char="." rowspan="1" colspan="1">0.002</td><td align="char" char="." rowspan="1" colspan="1">0.029</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Insulin (&#x003bc;U/mL)</td><td align="center" rowspan="1" colspan="1">19 &#x000b1; 1</td><td align="center" rowspan="1" colspan="1">12 &#x000b1; 1.2</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">14 &#x000b1; 1.7</td><td align="center" rowspan="1" colspan="1">19 &#x000b1; 2</td><td align="char" char="." rowspan="1" colspan="1">0.069</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="char" char="." rowspan="1" colspan="1">0.021</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">FBG (mg/dL)</td><td align="center" rowspan="1" colspan="1">114 &#x000b1; 7</td><td align="center" rowspan="1" colspan="1">111 &#x000b1; 9</td><td align="char" char="." rowspan="1" colspan="1">0.801</td><td align="center" rowspan="1" colspan="1">131 &#x000b1; 37</td><td align="center" rowspan="1" colspan="1">129 &#x000b1; 26</td><td align="char" char="." rowspan="1" colspan="1">0.970</td><td align="char" char="." rowspan="1" colspan="1">0.205</td><td align="char" char="." rowspan="1" colspan="1">0.688</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">HOMA</td><td align="center" rowspan="1" colspan="1">5.3 &#x000b1; 0.4</td><td align="center" rowspan="1" colspan="1">3.4 &#x000b1; 0.6</td><td align="char" char="." rowspan="1" colspan="1">0.023</td><td align="center" rowspan="1" colspan="1">4.5 &#x000b1; 1.2</td><td align="center" rowspan="1" colspan="1">6.2 &#x000b1; 0.5</td><td align="char" char="." rowspan="1" colspan="1">0.393</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="char" char="." rowspan="1" colspan="1">0.160</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">HbA<sub>1c</sub> (%)</td><td align="center" rowspan="1" colspan="1">6.4 &#x000b1; 0.2</td><td align="center" rowspan="1" colspan="1">6.6 &#x000b1; 0.4</td><td align="char" char="." rowspan="1" colspan="1">0.347</td><td align="center" rowspan="1" colspan="1">6.7 &#x000b1; 0.5</td><td align="center" rowspan="1" colspan="1">6.5 &#x000b1; 0.4</td><td align="char" char="." rowspan="1" colspan="1">0.770</td><td align="char" char="." rowspan="1" colspan="1">0.089</td><td align="char" char="." rowspan="1" colspan="1">0.656</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">8-Isoprostane (pg/mL)</td><td align="center" rowspan="1" colspan="1">233 &#x000b1; 17</td><td align="center" rowspan="1" colspan="1">141 &#x000b1; 18</td><td align="char" char="." rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1">236 &#x000b1; 25</td><td align="center" rowspan="1" colspan="1">313 &#x000b1; 77</td><td align="char" char="." rowspan="1" colspan="1">0.289</td><td align="char" char="." rowspan="1" colspan="1">0.053</td><td align="char" char="." rowspan="1" colspan="1">0.039</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Leptin (ng/mL)</td><td align="center" rowspan="1" colspan="1">38 &#x000b1; 0.6</td><td align="center" rowspan="1" colspan="1">26 &#x000b1; 2.6</td><td align="char" char="." rowspan="1" colspan="1">0.074</td><td align="center" rowspan="1" colspan="1">34 &#x000b1; 5</td><td align="center" rowspan="1" colspan="1">52 &#x000b1; 5</td><td align="char" char="." rowspan="1" colspan="1">0.023</td><td align="char" char="." rowspan="1" colspan="1">0.003</td><td align="char" char="." rowspan="1" colspan="1">0.044</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Adiponectin (&#x000b5;g/mL)</td><td align="center" rowspan="1" colspan="1">5.6 &#x000b1; 0.6</td><td align="center" rowspan="1" colspan="1">10.4 &#x000b1; 0.9</td><td align="char" char="." rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">7.7 &#x000b1; 0.7</td><td align="center" rowspan="1" colspan="1">4.6 &#x000b1; 0.5</td><td align="char" char="." rowspan="1" colspan="1">0.006</td><td align="char" char="." rowspan="1" colspan="1">0.003</td><td align="char" char="." rowspan="1" colspan="1">0.001</td></tr></tbody></table><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="left" scope="col" rowspan="1" colspan="1"/><th colspan="6" align="center" scope="colgroup" rowspan="1">Healthy control subjects</th><th align="left" scope="col" rowspan="1" colspan="1"/><th align="left" scope="col" rowspan="1" colspan="1"/></tr><tr><th rowspan="2" align="left" scope="col" colspan="1"/><th colspan="3" align="center" scope="colgroup" rowspan="1">AGE-restricted diet (<italic>n</italic> = 9)</th><th colspan="3" align="center" scope="colgroup" rowspan="1">Regular AGE diet (<italic>n</italic> = 9)</th><th rowspan="2" align="center" scope="col" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="t2n3">&#x02021;</xref></th><th rowspan="2" align="center" scope="col" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="t2n4">&#x000a7;</xref></th></tr><tr><th colspan="1" align="center" scope="colgroup" rowspan="1">Baseline</th><th align="center" scope="col" rowspan="1" colspan="1">End</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="t2n1">*</xref></th><th align="center" scope="col" rowspan="1" colspan="1">Baseline</th><th align="center" scope="col" rowspan="1" colspan="1">End</th><th align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="t2n2">&#x02020;</xref></th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1">sCML (units/mL)</td><td align="center" rowspan="1" colspan="1">12.4 &#x000b1; 0.5</td><td align="center" rowspan="1" colspan="1">9.3 &#x000b1; 1.0</td><td align="char" char="." rowspan="1" colspan="1">0.016</td><td align="center" rowspan="1" colspan="1">11.7 &#x000b1; 0.8</td><td align="center" rowspan="1" colspan="1">14.0 &#x000b1; 1</td><td align="char" char="." rowspan="1" colspan="1">0.168</td><td align="char" char="." rowspan="1" colspan="1">0.002</td><td align="char" char="." rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">sMG (nmol/mL)</td><td align="center" rowspan="1" colspan="1">1.1 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">0.9 &#x000b1; 0.1</td><td align="char" char="." rowspan="1" colspan="1">0.049</td><td align="center" rowspan="1" colspan="1">1.0 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">1.2 &#x000b1; 0.1</td><td align="char" char="." rowspan="1" colspan="1">0.330</td><td align="char" char="." rowspan="1" colspan="1">0.026</td><td align="char" char="." rowspan="1" colspan="1">0.052</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">iCML (units/mg)</td><td align="center" rowspan="1" colspan="1">5.5 &#x000b1; 1.0</td><td align="center" rowspan="1" colspan="1">7.0 &#x000b1; 1.2</td><td align="char" char="." rowspan="1" colspan="1">0.366</td><td align="center" rowspan="1" colspan="1">5.9 &#x000b1; 0.6</td><td align="center" rowspan="1" colspan="1">5.3 &#x000b1; 0.7</td><td align="char" char="." rowspan="1" colspan="1">0.502</td><td align="char" char="." rowspan="1" colspan="1">0.186</td><td align="char" char="." rowspan="1" colspan="1">0.256</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">iMG (nmol/mg)</td><td align="center" rowspan="1" colspan="1">0.63 &#x000b1; 0.12</td><td align="center" rowspan="1" colspan="1">0.76 &#x000b1; 0.18</td><td align="char" char="." rowspan="1" colspan="1">0.538</td><td align="center" rowspan="1" colspan="1">0.75 &#x000b1; 0.12</td><td align="center" rowspan="1" colspan="1">0.63 &#x000b1; 0.12</td><td align="char" char="." rowspan="1" colspan="1">0.514</td><td align="char" char="." rowspan="1" colspan="1">0.137</td><td align="char" char="." rowspan="1" colspan="1">0.552</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">AGER1 (mRNA)</td><td align="center" rowspan="1" colspan="1">226 &#x000b1; 46</td><td align="center" rowspan="1" colspan="1">207 &#x000b1; 45</td><td align="char" char="." rowspan="1" colspan="1">0.767</td><td align="center" rowspan="1" colspan="1">224 &#x000b1; 36</td><td align="center" rowspan="1" colspan="1">278 &#x000b1; 43</td><td align="char" char="." rowspan="1" colspan="1">0.345</td><td align="char" char="." rowspan="1" colspan="1">0.137</td><td align="char" char="." rowspan="1" colspan="1">0.270</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">RAGE (mRNA)</td><td align="center" rowspan="1" colspan="1">534 &#x000b1; 133</td><td align="center" rowspan="1" colspan="1">372 &#x000b1; 81</td><td align="char" char="." rowspan="1" colspan="1">0.323</td><td align="center" rowspan="1" colspan="1">413 &#x000b1; 65</td><td align="center" rowspan="1" colspan="1">628 &#x000b1; 136</td><td align="char" char="." rowspan="1" colspan="1">0.174</td><td align="char" char="." rowspan="1" colspan="1">0.001</td><td align="char" char="." rowspan="1" colspan="1">0.125</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">SIRT1 (mRNA)</td><td align="center" rowspan="1" colspan="1">383 &#x000b1; 34</td><td align="center" rowspan="1" colspan="1">288 &#x000b1; 100</td><td align="char" char="." rowspan="1" colspan="1">0.388</td><td align="center" rowspan="1" colspan="1">368 &#x000b1; 42</td><td align="center" rowspan="1" colspan="1">420 &#x000b1; 169</td><td align="char" char="." rowspan="1" colspan="1">0.783</td><td align="char" char="." rowspan="1" colspan="1">0.686</td><td align="char" char="." rowspan="1" colspan="1">0.634</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">TNF-&#x003b1; (ng/mg)</td><td align="center" rowspan="1" colspan="1">10.0 &#x000b1; 1.3</td><td align="center" rowspan="1" colspan="1">8.4 &#x000b1; 0.7</td><td align="char" char="." rowspan="1" colspan="1">0.293</td><td align="center" rowspan="1" colspan="1">8.6 &#x000b1; 0.6</td><td align="center" rowspan="1" colspan="1">11.8 &#x000b1; 1</td><td align="char" char="." rowspan="1" colspan="1">0.015</td><td align="char" char="." rowspan="1" colspan="1">0.002</td><td align="char" char="." rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Insulin (&#x003bc;U/mL)</td><td align="center" rowspan="1" colspan="1">10.6 &#x000b1; 1</td><td align="center" rowspan="1" colspan="1">11.3 &#x000b1; 2.4</td><td align="char" char="." rowspan="1" colspan="1">0.802</td><td align="center" rowspan="1" colspan="1">5.9 &#x000b1; 1.1</td><td align="center" rowspan="1" colspan="1">7.4 &#x000b1; 1.4</td><td align="char" char="." rowspan="1" colspan="1">0.437</td><td align="char" char="." rowspan="1" colspan="1">0.117</td><td align="char" char="." rowspan="1" colspan="1">0.198</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">FBG (mg/dL)</td><td align="center" rowspan="1" colspan="1">86 &#x000b1; 3</td><td align="center" rowspan="1" colspan="1">88 &#x000b1; 6</td><td align="char" char="." rowspan="1" colspan="1">0.710</td><td align="center" rowspan="1" colspan="1">83 &#x000b1; 4</td><td align="center" rowspan="1" colspan="1">80 &#x000b1; 4</td><td align="char" char="." rowspan="1" colspan="1">0.509</td><td align="char" char="." rowspan="1" colspan="1">0.785</td><td align="char" char="." rowspan="1" colspan="1">0.259</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">HOMA</td><td align="center" rowspan="1" colspan="1">2.2 &#x000b1; 0.3</td><td align="center" rowspan="1" colspan="1">2.5 &#x000b1; 0.6</td><td align="char" char="." rowspan="1" colspan="1">0.621</td><td align="center" rowspan="1" colspan="1">1.3 &#x000b1; 0.3</td><td align="center" rowspan="1" colspan="1">1.5 &#x000b1; 0.3</td><td align="char" char="." rowspan="1" colspan="1">0.755</td><td align="char" char="." rowspan="1" colspan="1">0.409</td><td align="char" char="." rowspan="1" colspan="1">0.122</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">8-Isoprostane (pg/mL)</td><td align="center" rowspan="1" colspan="1">135 &#x000b1; 10</td><td align="center" rowspan="1" colspan="1">90 &#x000b1; 9</td><td align="char" char="." rowspan="1" colspan="1">0.006</td><td align="center" rowspan="1" colspan="1">125 &#x000b1; 18</td><td align="center" rowspan="1" colspan="1">165 &#x000b1; 23</td><td align="char" char="." rowspan="1" colspan="1">0.198</td><td align="char" char="." rowspan="1" colspan="1">0.002</td><td align="char" char="." rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Leptin (ng/mL)</td><td align="center" rowspan="1" colspan="1">16 &#x000b1; 4</td><td align="center" rowspan="1" colspan="1">13 &#x000b1; 4</td><td align="char" char="." rowspan="1" colspan="1">0.675</td><td align="center" rowspan="1" colspan="1">14 &#x000b1; 4</td><td align="center" rowspan="1" colspan="1">17 &#x000b1; 6</td><td align="char" char="." rowspan="1" colspan="1">0.673</td><td align="char" char="." rowspan="1" colspan="1">0.386</td><td align="char" char="." rowspan="1" colspan="1">0.634</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Adiponectin (&#x000b5;g/mL)</td><td align="center" rowspan="1" colspan="1">16 &#x000b1; 4</td><td align="center" rowspan="1" colspan="1">15.6 &#x000b1; 4</td><td align="char" char="." rowspan="1" colspan="1">0.882</td><td align="center" rowspan="1" colspan="1">16 &#x000b1; 4</td><td align="center" rowspan="1" colspan="1">18 &#x000b1; 3</td><td align="char" char="." rowspan="1" colspan="1">0.698</td><td align="char" char="." rowspan="1" colspan="1">0.102</td><td align="char" char="." rowspan="1" colspan="1">0.683</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as mean &#x000b1; SEM. FBG, fasting blood glucose.</p></fn><fn id="t2n1"><p>*Statistical significance between baseline and end of study means in the AGE-restricted diet group.</p></fn><fn id="t2n2"><p>&#x02020;Statistical significance between baseline and end of study means in the regular AGE diet group.</p></fn><fn id="t2n3"><p>&#x02021;Statistical significance in percentage change between baseline and end of study between the AGE-restricted diet and the regular diet groups.</p></fn><fn id="t2n4"><p>&#x000a7;Statistical significance between the means of both groups at the end of the study.</p></fn></table-wrap-foot></table-wrap><fig id="F1" fig-type="figure" position="float"><label>Figure 1</label><caption><p><italic>A</italic>: AGE restriction reduces IR and improves inflammation in type 2 diabetic patients. Changes after AGE restriction (&#x000d7;4 months) in circulating factors (by ELISAs), plasma insulin, and HOMA, leptin, adiponectin, serum CML, MG, or in PMNCs, and AGER1, SIRT1, RAGE mRNA (by RT-PCR), are shown as percentage (mean &#x000b1; SEM) above or below the baseline. *<italic>P</italic> &#x0003c; 0.050. <italic>Inset:</italic> Leptin (Lep)/adiponectin (Adipo) ratio before and after treatment is shown relative to normal control subjects (NL, at baseline, open bars). <italic>B</italic>: AGE restriction enhances SIRT1 and AGER1 protein expression in PMNCs of type 2 diabetic patients. PMNCs obtained at entry (<italic>1</italic>) and at the end of the study (<italic>2</italic>) are shown for subjects exposed to AGE restriction (AGE-Restr) vs. regular diet (Reg). SIRT1 and AGER1 protein levels were assessed by Western blotting (<italic>upper panels</italic>), followed by densitometric analysis (<italic>lower panels</italic>). <italic>C</italic>: AGE restriction enhances SIRT1 deacetylation of NF-&#x003ba;B p65. Levels of NF-&#x003ba;B p65 acetylation are shown at entry (<italic>1</italic>) and at the end of study (<italic>2</italic>) after immunoprecipitation (IP) and immunoblotting (IB) against acetyl-lysine residues. Data are shown as the percentage (mean &#x000b1; SEM) change from entry (<italic>1</italic>). <italic>P</italic> values are as indicated.</p></caption><graphic xlink:href="1610fig1"/></fig><p>Type 2 diabetic subjects on the regular diet showed no significant changes, except for higher sMG, iCML, leptin, and TNF-&#x003b1; values (<xref ref-type="table" rid="T2">Table 2</xref>), consistent with sustained high AGE intake and AGE accumulation. Neither the diabetic patients nor the healthy subjects had changes in weight (96.0 &#x000b1; 7 to 97.3 &#x000b1; 8 kg vs. 83.6 &#x000b1; 6 to 82.0 &#x000b1; 6 kg, respectively), BMI, plasma lipids, blood glucose, or HbA<sub>1c</sub> after 4 months. Healthy subjects on the AGE-restricted diet had no significant changes, with the exception of decreased sAGEs and 8-isoprostanes (<xref ref-type="table" rid="T2">Table 2</xref>).</p></sec><sec id="s22"><title>PMNC changes in the AGE-restriction cohort.</title><p>The suppressed basal mRNA levels of AGER1 and SIRT1 in type 2 diabetic patients were increased by &#x0223c;50%, almost to the normal range in the AGE-restricted cohort (<xref ref-type="fig" rid="F1">Fig. 1<italic>A</italic></xref>; <xref ref-type="table" rid="T2">Table 2</xref>) (<xref ref-type="bibr" rid="B9">9</xref>). The changes in mRNA of AGER1 and SIRT1 correlated with changes in protein expression (<xref ref-type="fig" rid="F1">Fig. 1<italic>B</italic></xref>). Intracellular AGE levels in the AGE-restricted group were decreased, iMG (<italic>P</italic> = 0.002) and iCML (<italic>P</italic> = 0.148; <xref ref-type="table" rid="T2">Table 2</xref>), consistent with increased AGER1 expression.</p><p>There was also a reduction in NF-&#x003ba;B acetyl-p65 (<xref ref-type="fig" rid="F1">Fig. 1<italic>C</italic></xref>), associated with trends of lower RAGE mRNA and TNF-&#x003b1; protein in PMNCs from AGE-restricted type 2 diabetic subjects (<xref ref-type="table" rid="T2">Table 2</xref>). In contrast, in diabetic subjects who ate the regular diet, PMNC SIRT1 remained depressed (<xref ref-type="fig" rid="F1">Fig. 1<italic>B</italic> and <italic>C</italic></xref>; <xref ref-type="table" rid="T2">Table 2</xref>), whereas acetyl-p65, TNF-&#x003b1;, and RAGE remained elevated in diabetic subjects, consistent with higher circulating oxidants, AGEs, and 8-isoprostane (<xref ref-type="table" rid="T2">Table 2</xref>).</p></sec></sec><sec id="s23"><title>In vitro effects of AGEs on THP-1 AGER1 and SIRT1 expression and function</title><p>Because SIRT1 (<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B23">23</xref>) and AGER1 (<xref ref-type="bibr" rid="B6">6</xref>&#x02013;<xref ref-type="bibr" rid="B8">8</xref>) are suppressed in patients with diabetes (high OS), monocyte-like THP-1 cells were used as inflammatory cells to investigate the observations in PMNCs. AGER1 and SIRT1 protein expression levels were coordinately suppressed in THP-1 cells after chronic exposure to CML or MG (but not unmodified BSA; <xref ref-type="fig" rid="F2">Fig. 2<italic>A</italic></xref>). In addition, AGER1 and SIRT1 expression was enhanced in AGER1-overexpressing (AGER1<sup>+</sup>) cells treated with MG but reduced in AGER1-silenced THP-1 cells (<xref ref-type="fig" rid="F2">Fig. 2<italic>B</italic> and <italic>C</italic></xref>). After a transient induction, a marked time&#x02013;dependent reduction of the NAD<sup>+</sup>/NADH ratio was noted in association with suppressed SIRT1 levels, and this effect was prevented by antioxidants (NAC, apocynin; Fig. 2<italic>D</italic>) and by AGER1 overexpression (AGER1<sup>+</sup>; <xref ref-type="fig" rid="F2">Fig. 2<italic>E</italic></xref>). In addition, the AGE-induced NF-&#x003ba;B p65 hyperacetylation seen in wild-type cells was blocked in AGER1<sup>+</sup> cells (<xref ref-type="fig" rid="F2">Fig. 2<italic>F</italic></xref>), consistent with preserved SIRT1 function when AGER1 is intact. These data were in line with the PMNC findings from type 2 diabetic patients.</p><fig id="F2" fig-type="figure" position="float"><label>Figure 2</label><caption><p>AGEs suppress AGER1, SIRT1 protein, and NAD<sup>+</sup> levels as well as NF-&#x003ba;B p65 deacetylation in THP-1 cells. <italic>A</italic>: Western blots (<italic>upper panels</italic>) and densitometry (<italic>lower panels</italic>) results are shown for AGER1 (black bars) and SIRT1 (gray bars) protein expression in THP-1 cells (wild-type [WT]) stimulated with CML-BSA (150 &#x003bc;g/mL), MG-BSA (60 &#x003bc;g/mL), and BSA (60 &#x003bc;g/mL) for 72 h. <italic>B</italic> and <italic>C</italic>: MG-induced effects on SIRT1 are AGER1-dependent. WT or THP-1 cells transfected with AGER1 (AGER1<sup>+</sup>) or short-hairpin RNA for AGER1 (shAGER1) were stimulated by MG (60 &#x003bc;g/mL) for 24 h before Western blots (<italic>upper panels</italic>) and densitometry plots (<italic>lower panels;</italic> AGER1, black bars; SIRT1, gray bars; WT, open bars). Data (mean &#x000b1; SEM) of three to five experiments, derived from test/&#x003b2;-actin ratio, are shown as fold above control (cells alone, WT). *<italic>P</italic> &#x0003c; 0.001 vs. BSA or cells alone. #<italic>P</italic> &#x0003c; 0.002 vs. maximal values. <italic>D</italic> and<italic> E</italic>: AGE-induced effects on SIRT1 are NAD<sup>+</sup>-dependent and regulated by OS (<italic>D</italic>) and AGER1 (<italic>E</italic>). THP-1 cells were cultured with MG-BSA (60 &#x003bc;g/mL) or media (CL) for up to 72 h prior to Western blotting for SIRT1 (<italic>top inset</italic>) and NAD<sup>+</sup>/NADH ratio in the presence or absence of antioxidants (NAC or apocynin) in WT or AGER1<sup>+</sup>-transduced cells (<italic>E</italic>). NAD<sup>+</sup>/NADH ratio is shown as fold (mean &#x000b1; SE) above control (<italic>n</italic> = 3, each in triplicate). *<italic>P</italic> &#x0003c; 0.001 vs. control. &#x000a7;<italic>P</italic> &#x0003c; 0.002 vs. maximal increase. <italic>F</italic>: NF-&#x003ba;B p65 hyperacetylation is induced by AGEs but is blocked by AGER1. Acetyl-p65 was determined in THP-1 cells, after MG stimulation (60 &#x003bc;g/mL) for 72 h in the presence or absence of SIRT1 inhibitor, sirtinol (10 &#x003bc;mol/L). Western blots and density plots are shown as mean &#x000b1; SEM from four independent experiments. *<italic>P</italic> &#x0003c; 0.002 vs. nonstimulated or vs. nontransduced THP-1 cells.</p></caption><graphic xlink:href="1610fig2"/></fig></sec></sec><sec sec-type="conclusions" id="s24"><title>CONCLUSIONS</title><p>IR remains an unresolved scientific and therapeutic problem. Increased OS and impaired anti-OS defenses are important factors in the development and persistence of IR (<xref ref-type="bibr" rid="B2">2</xref>&#x02013;<xref ref-type="bibr" rid="B4">4</xref>). The current study shows that AGE restriction can improve IR in type 2 diabetes. Plasma insulin, markers of inflammation, and OS were substantially improved in diabetic subjects by an intervention that restricts oxidant (AGE) load without altering energy balance. These findings are consistent with evidence showing that excessive food AGEs promote inflammation and OS in humans (<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B19">19</xref>) and IR in mice (<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>). That plasma insulin was nearly normalized after the AGE restriction indicates that tissue glucose uptake was improved. Therefore, a reduced demand on &#x003b2;-cells for insulin release appears to be directly related to the AGE restriction. While the findings must be confirmed in larger cohorts, AGE restriction may have therapeutic advantages in IR.</p><p>Although endogenous glucose or lipids contribute to elevated AGEs (<xref ref-type="bibr" rid="B22">22</xref>), exogenously AGE-modified nutrients are an important source in both human subjects and animals (<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>). The significant reduction in serum AGEs and lipid peroxides (8-isoprostanes) after AGE restriction in the current study confirms the hypothesis that elevated AGEs in type 2 diabetes result from increased dietary AGE intake, independently from glycemic control (<xref ref-type="bibr" rid="B19">19</xref>).</p><p>AGE restriction normalized AGER1, SIRT1, and SIRT1-dependent NF-&#x003ba;B p65 deacetylation levels, and there was a concomitant attenuation of proinflammatory mediators (i.e., RAGE and TNF-&#x003b1;) (<xref ref-type="bibr" rid="B9">9</xref>). The decreased basal AGER1 and SIRT1 (mRNA and protein) levels in type 2 diabetic PMNCs suggests a link between these two mechanisms. Since plasma insulin and leptin levels fell, whereas adiponectin levels increased with AGE restriction, the changes in AGER1 expression reflected adjustments in both the inflammatory and the metabolic states, effects previously attributed to SIRT1 (<xref ref-type="bibr" rid="B2">2</xref>&#x02013;<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B23">23</xref>). Thus, high AGE and low AGER1 levels in type 2 diabetes may partly account for the persistence of IR in these patients.</p><p>Given that downregulation of AGER1 (<xref ref-type="bibr" rid="B7">7</xref>&#x02013;<xref ref-type="bibr" rid="B9">9</xref>) and SIRT1 is linked to high OS conditions (<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>), the current findings also indicate that normal SIRT1 function may depend on the ability of intact AGER1 to control AGEs and OS. Thus, the loss of AGER1 function may be one mechanism leading to SIRT1 downregulation in type 2 diabetes. This postulate is supported in the current study by the high basal levels of intracellular AGEs and low AGER1 levels in type 2 diabetic PMNC. The fact that these levels are nearly normalized after AGE restriction lends further support to this hypothesis. These data also suggest that low steady-state levels of intracellular AGEs may be crucial for maintaining AGER1 intact (<xref ref-type="bibr" rid="B7">7</xref>&#x02013;<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B24">24</xref>).</p><p>Because this was the first time that AGEs and AGER1 were linked to the deacetylases and to SIRT1, we probed these relationships in inflammatory monocyte&#x02013;like THP-1 cells. After prolonged exposure to AGEs, AGER1 and SIRT1 were both suppressed in these cells or became unresponsive. AGEs acted via an OS-dependent decrease in NAD<sup>+</sup>, explaining the eventual downregulation of SIRT1, and consequently, the hyperacetylation of NF-&#x003ba;B p65 observed in diabetic PMNCs (<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B4">4</xref>). Since the AGE-induced effects on SIRT1 and NF-&#x003ba;B were blocked in THP-1 cells by genetic modulation of AGER1 expression, AGER1 is likely to be involved in the regulation of inflammatory responses controlled by SIRT1. The data also suggest that controlling the pro-oxidant effects of AGEs could help preserve normal AGER1 and SIRT1 functions.</p><p>From a clinical perspective, AGE restriction markedly increased adiponectin levels and reduced the initially high leptin/adiponectin ratio, a marker of IR, indicating that AGEs also affect insulin-sensitive tissues (<xref ref-type="bibr" rid="B2">2</xref>&#x02013;<xref ref-type="bibr" rid="B5">5</xref>). Adiponectin improves insulin sensitivity and is controlled by SIRT1 (<xref ref-type="bibr" rid="B25">25</xref>); therefore, the doubling in adiponectin levels after AGE-restriction provides another insight into the improved metabolic state in type 2 diabetic patients.</p><p>These data show that chronic exposure to excessive exogenous (food) oxidants fosters an impairment in both native antioxidant defenses as well as insulin action and that reducing oral AGEs can ameliorate these defects. This approach does not restrict energy or caloric intake. Since the effects of AGE restriction were additive to standard medical therapy, the intervention could be a valuable addition to the current management of patients with type 2 diabetes. Larger trials are warranted to validate the findings and establish the long-term effects of this intervention on diabetes.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by MERIT grants AG-23188 and AG-09453 (to H.V.) and from the National Institutes of Health, National Institute of Research Resources (Grant M01-RR-00071) to the General Clinical Research Center at Mount Sinai School of Medicine for clinical and statistical support.</p><p>No potential conflicts of interest relevant to this article were reported.</p><p>J.U. researched the data and reviewed and edited the manuscript. W.C. researched the data and wrote, reviewed, and edited the manuscript. M.R. researched the data. S.G. researched the data and contributed to the discussion. R.P., X.C., and L.Z. researched the data. G.E.S. reviewed and edited the manuscript. H.V. designed the study, obtained support, researched the data, contributed to the discussion, and wrote, reviewed, and edited the manuscript.</p><p>Part of this study was submitted in abstract form to the 71st Scientific Sessions of the American Diabetes Association, 24&#x02013;28 June 2011, San Diego, California.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haigis</surname><given-names>MC</given-names></name><name><surname>Sinclair</surname><given-names>DA</given-names></name></person-group> <article-title>Mammalian sirtuins: biological insights and disease relevance</article-title>. <source>Annu Rev Pathol</source> <year>2010</year>;<volume>5</volume>:<fpage>253</fpage>&#x02013;<lpage>295</lpage><pub-id pub-id-type="pmid">20078221</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>F</given-names></name><name><surname>Kume</surname><given-names>S</given-names></name><name><surname>Koya</surname><given-names>D</given-names></name></person-group> <article-title>SIRT1 and insulin resistance</article-title>. <source>Nat Rev Endocrinol</source> <year>2009</year>;<volume>5</volume>:<fpage>367</fpage>&#x02013;<lpage>373</lpage><pub-id pub-id-type="pmid">19455179</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olefsky</surname><given-names>JM</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name></person-group> <article-title>Macrophages, inflammation, and insulin resistance</article-title>. <source>Annu Rev Physiol</source> <year>2010</year>;<volume>72</volume>:<fpage>219</fpage>&#x02013;<lpage>246</lpage><pub-id pub-id-type="pmid">20148674</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Kreutzenberg</surname><given-names>SV</given-names></name><name><surname>Ceolotto</surname><given-names>G</given-names></name><name><surname>Papparella</surname><given-names>I</given-names></name><etal/></person-group> <article-title>Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms</article-title>. <source>Diabetes</source> <year>2010</year>;<volume>59</volume>:<fpage>1006</fpage>&#x02013;<lpage>1015</lpage><pub-id pub-id-type="pmid">20068143</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardellini</surname><given-names>M</given-names></name><name><surname>Menghini</surname><given-names>R</given-names></name><name><surname>Martelli</surname><given-names>E</given-names></name><etal/></person-group> <article-title>TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1</article-title>. <source>Diabetes</source> <year>2009</year>;<volume>58</volume>:<fpage>2396</fpage>&#x02013;<lpage>2401</lpage><pub-id pub-id-type="pmid">19581416</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>CJ</given-names></name><name><surname>Koschinsky</surname><given-names>T</given-names></name><name><surname>Buenting</surname><given-names>C</given-names></name><name><surname>Vlassara</surname><given-names>H</given-names></name></person-group> <article-title>Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE</article-title>. <source>Mol Med</source> <year>2001</year>;<volume>7</volume>:<fpage>159</fpage>&#x02013;<lpage>168</lpage><pub-id pub-id-type="pmid">11471552</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>JC</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Vlassara</surname><given-names>H</given-names></name></person-group> <article-title>Advanced glycation end product (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2004</year>;<volume>102</volume>:<fpage>11767</fpage>&#x02013;<lpage>11772</lpage><pub-id pub-id-type="pmid">15289604</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>JC</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Vlassara</surname><given-names>H</given-names></name></person-group> <article-title>Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2006</year>;<volume>103</volume>:<fpage>13801</fpage>&#x02013;<lpage>13806</lpage><pub-id pub-id-type="pmid">16954185</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlassara</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Goodman</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1</article-title>. <source>J Clin Endocrinol Metab</source> <year>2009</year>;<volume>94</volume>:<fpage>4483</fpage>&#x02013;<lpage>4491</lpage><pub-id pub-id-type="pmid">19820033</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Giles</surname><given-names>WH</given-names></name><name><surname>Mokdad</surname><given-names>AH</given-names></name></person-group> <article-title>Increasing prevalence of the metabolic syndrome among U.S. adults</article-title>. <source>Diabetes Care</source> <year>2004</year>;<volume>27</volume>:<fpage>2444</fpage>&#x02013;<lpage>2449</lpage><pub-id pub-id-type="pmid">15451914</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riccardi</surname><given-names>G</given-names></name><name><surname>Giacco</surname><given-names>R</given-names></name><name><surname>Rivellese</surname><given-names>AA</given-names></name></person-group> <article-title>Dietary fat, insulin sensitivity and the metabolic syndrome</article-title>. <source>Clin Nutr</source> <year>2004</year>;<volume>23</volume>:<fpage>447</fpage>&#x02013;<lpage>456</lpage><pub-id pub-id-type="pmid">15297079</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>VS</given-names></name><name><surname>Popkin</surname><given-names>BM</given-names></name><name><surname>Bray</surname><given-names>GA</given-names></name><name><surname>Despr&#x000e9;s</surname><given-names>JP</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name></person-group> <article-title>Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk</article-title>. <source>Circulation</source> <year>2010</year>;<volume>121</volume>:<fpage>1356</fpage>&#x02013;<lpage>1364</lpage><pub-id pub-id-type="pmid">20308626</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoelson</surname><given-names>SE</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Goldfine</surname><given-names>AB</given-names></name></person-group> <article-title>Inflammation and insulin resistance</article-title>. <source>J Clin Invest</source> <year>2006</year>;<volume>116</volume>:<fpage>1793</fpage>&#x02013;<lpage>1801</lpage><pub-id pub-id-type="pmid">16823477</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koschinsky</surname><given-names>T</given-names></name><name><surname>He</surname><given-names>CJ</given-names></name><name><surname>Mitsuhashi</surname><given-names>T</given-names></name><etal/></person-group> <article-title>Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy</article-title>. <source>Proc Natl Acad Sci USA</source> <year>1997</year>;<volume>94</volume>:<fpage>6474</fpage>&#x02013;<lpage>6479</lpage><pub-id pub-id-type="pmid">9177242</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>SM</given-names></name><name><surname>Dong</surname><given-names>HJ</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group> <article-title>Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse</article-title>. <source>Diabetes</source> <year>2002</year>;<volume>51</volume>:<fpage>2082</fpage>&#x02013;<lpage>2089</lpage><pub-id pub-id-type="pmid">12086936</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>JC</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><etal/></person-group> <article-title>Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan</article-title>. <source>Am J Pathol</source> <year>2008</year>;<volume>173</volume>:<fpage>327</fpage>&#x02013;<lpage>336</lpage><pub-id pub-id-type="pmid">18599606</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>RY</given-names></name><name><surname>Reis</surname><given-names>ED</given-names></name><name><surname>Dore</surname><given-names>AT</given-names></name><etal/></person-group> <article-title>Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice</article-title>. <source>Atherosclerosis</source> <year>2002</year>;<volume>163</volume>:<fpage>303</fpage>&#x02013;<lpage>311</lpage><pub-id pub-id-type="pmid">12052477</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Hattori</surname><given-names>M</given-names></name><name><surname>Steffes</surname><given-names>M</given-names></name><name><surname>Vlassara</surname><given-names>H</given-names></name></person-group> <article-title>Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products</article-title>. <source>Diabetes Metab Res Rev</source> <year>2002</year>;<volume>18</volume>:<fpage>224</fpage>&#x02013;<lpage>237</lpage><pub-id pub-id-type="pmid">12112941</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vlassara</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Crandall</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy</article-title>. <source>Proc Natl Acad Sci USA</source> <year>2002</year>;<volume>99</volume>:<fpage>15596</fpage>&#x02013;<lpage>15601</lpage><pub-id pub-id-type="pmid">12429856</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uribarri</surname><given-names>J</given-names></name><name><surname>Woodruff</surname><given-names>S</given-names></name><name><surname>Goodman</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Advanced glycation end products in foods and a practical guide to their reduction in the diet</article-title>. <source>J Am Diet Assoc</source> <year>2010</year>;<volume>110</volume>:<fpage>911</fpage>&#x02013;<lpage>916, e12</lpage><pub-id pub-id-type="pmid">20497781</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>QD</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Peppa</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Vlassara</surname><given-names>H</given-names></name></person-group> <article-title>Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction</article-title>. <source>Mol Med</source> <year>2002</year>;<volume>8</volume>:<fpage>337</fpage>&#x02013;<lpage>346</lpage><pub-id pub-id-type="pmid">12393931</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilhovd</surname><given-names>BK</given-names></name><name><surname>Juutilainen</surname><given-names>A</given-names></name><name><surname>Lehto</surname><given-names>S</given-names></name><etal/></person-group> <article-title>High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2005</year>;<volume>25</volume>:<fpage>815</fpage>&#x02013;<lpage>820</lpage><pub-id pub-id-type="pmid">19103747</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshizaki</surname><given-names>T</given-names></name><name><surname>Milne</surname><given-names>JC</given-names></name><name><surname>Imamura</surname><given-names>T</given-names></name><etal/></person-group> <article-title>SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes</article-title>. <source>Mol Cell Biol</source> <year>2009</year>;<volume>29</volume>:<fpage>1363</fpage>&#x02013;<lpage>1374</lpage><pub-id pub-id-type="pmid">15692098</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torreggiani</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia</article-title>. <source>Am J Pathol</source> <year>2009</year>;<volume>175</volume>:<fpage>1722</fpage>&#x02013;<lpage>1732</lpage><pub-id pub-id-type="pmid">19779136</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>L</given-names></name><name><surname>Shao</surname><given-names>J</given-names></name></person-group> <article-title>SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein &#x003b1; transcriptional complex</article-title>. <source>J Biol Chem</source> <year>2006</year>;<volume>281</volume>:<fpage>39915</fpage>&#x02013;<lpage>39924</lpage><pub-id pub-id-type="pmid">17090532</pub-id></mixed-citation></ref></ref-list></back></article>